Dr. Gohar Arslan, MD

Dr. Arslan practices at Sentora Southside Hematology & Oncology in South Boston, Virginia.

Dr. Arslan's NPI, 1053351544, was assigned on June 7, 2006. Dr. Arslan holds Pennsylvania license MD061486L.

Dr. Arslan's primary practice is Sentora Southside Hematology & Oncology, at 2232 Wilborn Ave, South Boston, VA 24592 in Halifax County. The practice phone is (434) 517-3640.

Dr. Arslan's primary practice is Sentora Southside Hematology & Oncology in South Boston, Virginia. Dr. Arslan is also affiliated with Sentara Halifax Regional Hospital. The medical group on file is Sentara Halifax General Surgery. Dmand AI also links Dr. Arslan to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arslan practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Arslan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Arslan is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Arslan's licenses on file in 2 states: Pennsylvania and Virginia.

CMS data shows 68 Medicare services from Dr. Arslan across 2 procedure codes in 2024, all of them office visits, for 49 Medicare patients. Medicare paid $3,165 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 49 Medicare patients who saw Dr. Arslan in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Arslan's median patient age at 66, with 60% women.

In 2024, Dr. Arslan wrote 118 Medicare Part D claims for 41 patients. 85% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $324 in total drug cost. In 2023, CMS named 472 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Arslan for performance year 2024, reported through an alternative payment model (APM). Dr. Arslan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 24 general payments to Dr. Arslan from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 85% of the total. Sanofi and Genzyme US Companies paid the most, $136.